4-(6,7-Dimethoxy-quinoxalin-2-ylamino)-cyclohexanol | 216699-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(6,7-Dimethoxy-quinoxalin-2-ylamino)-cyclohexanol
• 英文别名: 4-[(6,7-dimethoxyquinoxalin-2-yl)amino]cyclohexan-1-ol
• CAS: 216699-96-6
• 化学式: C₁₆H₂₁N₃O₃
• 分子量: 303.36
• InChiKey: CYVRFHRDWQAJGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  76.5
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR
  申请人：Uenaka Toshimitsu

  公开号：US20100092490A1

  公开（公告）日：2010-04-15

  The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.

  本发明提供了一种预测抗血管生成抑制剂的抗肿瘤效果的方法。通过评估肿瘤细胞对表皮生长因子（EGF）增殖和/或存活的依赖性，并将其作为指标，可以预测抗血管生成抑制剂的抗肿瘤效果。由于抗血管生成抑制剂的抗肿瘤效果与肿瘤细胞对EGF增殖和/或存活的依赖性相关，因此当与具有EGF抑制活性的物质结合时，抗血管生成抑制剂能够产生出色的抗肿瘤效果。
• [EN] QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSES DE QUINOLEINE ET QUINOXALINE UTILISES COMME INHIBITEURS DU RECEPTEUR PDGF ET/OU DE LA TYROSINE KINASE LCK
  申请人：AVENTIS PHARM PROD INC

  公开号：WO2000031051A1

  公开（公告）日：2000-06-02

  This invention is directed to quinoline/quinoxaline compounds of formula (I), which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising theses compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及公式（I）的喹啉/喹噁啉化合物，其抑制血小板来源性生长因子或p56lck酪氨酸激酶活性，以及包含这些化合物的制药组合物，并且用于治疗患有或受到涉及细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/症状的患者。
• [EN] QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSES DE QUINOLINE ET DE QUINOXALINE AGISSANT COMME INHIBITEURS DU PDGG-R ET/OU DE LCK TYROSINE KINASE
  申请人：AVENTIS PHARM PROD INC

  公开号：WO2000031049A1

  公开（公告）日：2000-06-02

  This invention is directed to quinoline/quinoxaline compounds of formula (I) wherein X is L1OH or L2Z2; L1 is (CR3aR3b)r or (CR3aR3b)m-Z3-(CR3'aR3'b)n; L2 is (CR3aR3b)p-Z4-(CR3'aR3'b)q or ethenyl; Z1 is CH or N; Z2 is optionally substituted hydroxycycloalkyl, optionally substituted hydroxycycloalkenyl, optionally substituted hydroxyheterocyclyl or optionally substituted hydroxyheterocyclenyl; Z3 is O, NR4, S, SO or SO2; Z4 is O, NR4, S, SO, SO2 or a bond; m is 0 or 1; n is 2 or 3, and n + m = 2 or 3; p and q are independently 0, 1, 2, 3 or 4, and p + q = 0, 1, 2, 3 or 4 when Z4 is a bond, and p + q = 0, 1, 2 or 3 when Z4 is other than a bond; r is 2, 3 or 4; which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及公式（I）的喹啉/喹噁啉化合物，其中X为L1OH或L2Z2; L1为（CR3aR3b）r或（CR3aR3b）m-Z3-（CR3'aR3'b）n; L2为（CR3aR3b）p-Z4-（CR3'aR3'b）q或乙烯基; Z1为CH或N; Z2为可选择取代的羟基环烷基，可选择取代的羟基环烯基，可选择取代的羟基杂环基或可选择取代的羟基杂环烷基; Z3为O，NR4，S，SO或SO2; Z4为O，NR4，S，SO，SO2或键; m为0或1; n为2或3，且n + m = 2或3; p和q独立地为0、1、2、3或4，当Z4为键时，p + q = 0、1、2、3或4，当Z4不是键时，p + q = 0、1、2或3; r为2、3或4; 这些化合物抑制血小板来源生长因子或p56lck酪氨酸激酶活性，本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗患有或患有涉及细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/症状的患者的用途。
• Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
  申请人：——

  公开号：US20010023250A1

  公开（公告）日：2001-09-20

  This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及抑制血小板源性生长因子或p56lck酪氨酸激酶活性的喹啉/喹噁啉化合物，以及包含这些化合物的制药组合物，以及使用这些化合物治疗患有或受到涉及细胞分化，增殖，细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/病症的患者。
• Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases
  申请人：——

  公开号：US20030139400A1

  公开（公告）日：2003-07-24

  This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及抑制血小板源性生长因子或p56lck酪氨酸激酶活性的喹啉/喹噁啉化合物，以及包含这些化合物的制药组合物，并且涉及使用这些化合物治疗患有或存在细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/状况的患者。